Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
The articles provided are largely summaries/titles without substantive content accessible for review (most are links with minimal or no extracted text). However, articles [9], [10], [12] from Medical Economics, Innovaccer, and NAACOS respectively contain meaningful signals: health care leaders are planning around ACCESS but doubting its financial payoff, and NAACOS/Innovaccer research finds organizations are shifting tech strategy in response to ACCESS. Article [14] from MedCity News frames ACCESS as attempting to succeed where value-based care has failed. These represent real implementation-era sentiment and strategic response data that the existing analysis — written from a model-design perspective — does not address.
These articles add a materially new dimension: early-stage market skepticism and technology strategy adaptation by ACOs and health care leaders, which is distinct from the design-focused analysis in the existing VE's Take. This warrants a targeted addition to the Competitive Positioning section and a new implementation risk note. The core architecture, financial, and stakeholder sections remain accurate.
ACCESS is CMMI's most consequential structural experiment since ACO REACH: it creates a third payment rail in Original Medicare alongside FFS and shared savings, purpose-built for a class of organizations that has never had a viable Medicare payment pathway. The model's architecture reflects a deliberate strategic posture — CMMI is not trying to reform incumbent providers; it is importing a commercially-proven care delivery sector into Medicare wholesale.
The Outcome-Aligned Payment (OAP) design makes a specific regulatory bet: that flat, outcome-contingent per-patient payments will generate better value than activity-based codes. The four initial tracks — eCKM, CKM, MSK, BH — were selected precisely because they have measurable biomarker or PROM endpoints that can anchor outcome accountability. This is not incidental. The specific targets are clinically defensible and administratively auditable: a 15 mmHg systolic BP reduction or final SBP <130 mmHg, a 5-point PHQ-9 reduction, a 2-point PROMIS PI reduction. These are not aspirational — they are the floor, not the ceiling.
The FFS Exclusion is the model's sharpest structural edge and its most consequential hidden risk. Once a patient is aligned, the ACCESS Participant and all affiliated entities (defined at 5%+ ownership interest or operational control) cannot bill any FFS codes for that beneficiary during the active care period. Only ACCESS G-codes may be submitted. Organizations with existing FFS revenue streams tied to the same patient population — a physical therapy group that also treats back pain, a cardiologist practice that also manages hypertension — face genuine revenue displacement, not supplement. The affiliation definition is broad enough to capture most common ownership arrangements.
The Substitute Spend Adjustment operates as a second accountability layer with real teeth: if more than 10% of aligned beneficiaries receive listed substitute services from other Medicare providers (e.g., a new PT evaluation while the MSK track is active, or DSMT initiation during eCKM enrollment), payment is proportionally reduced up to a 25% cap. This is explicitly designed to prevent ACCESS from becoming an add-on to existing FFS utilization — and ACOs should model this carefully before referring patients.
One underappreciated design feature: the randomized control group. ACCESS includes a true randomized evaluation — some eligible beneficiaries will be assigned to a control group and locked out for 12 months. This is CMMI running a genuine RCT, which signals the model's long-term ambition: if ACCESS demonstrates net Medicare savings, it becomes a permanent payment option or the basis for rulemaking. The 10-year timeline (through June 30, 2036) and rolling application window through April 1, 2033 support this interpretation.
The April 1, 2027 track expansion — adding heart failure, COPD, substance use disorder, and tobacco cessation without requiring reapplication — is a significant option value for early participants. Organizations that enter in the first or second cohort will have established operational infrastructure before competitors in those higher-complexity tracks.
Payment rates are modest in absolute terms but structurally favorable for low-marginal-cost care delivery models:
| Track | Initial Period | Follow-On Period |
|---|---|---|
| eCKM | $360/year ($30/month) | $180/year ($15/month) |
| CKM | $420/year ($35/month) | $210/year ($17.50/month) |
| MSK | $180/year ($15/month) | None |
| BH | $180/year ($15/month) | $90/year ($7.50/month) |
At these rates, a digitally-native organization with low per-patient marginal costs (an AI-coached MSK platform, a remote cardiometabolic clinic) can reach positive unit economics at patient volumes that traditional provider organizations cannot. Consider the MSK break-even scenario: at $180/year per patient with a 90%+ outcome attainment rate, an organization needs approximately 2,000–3,000 aligned beneficiaries to generate $360,000–$540,000 in gross annual ACCESS revenue — meaningful only if per-patient marginal cost (platform, clinical oversight, PROMs collection) is below $150–180/patient/year.
Cash flow structure requires planning. The model pays 100% of the annual OAP in monthly installments during months 1–6 (each monthly payment equals 1/12 of the annual rate), then withholds all payments in months 7–12, reconciling after the 12-month care period. A participant with 1,000 eCKM patients in steady state carries a withheld balance of approximately $180,000 ($360 × 1,000 × 50%) awaiting reconciliation. Organizations without reserve capital will face working capital pressure during ramp-up.
The Clinical Outcome Adjustment is survivable at the 50% OAT floor but cannot be taken for granted. An organization achieving only a 40% OAR receives 80% of total annual OAP — an effective 20% revenue haircut. At 1,000 eCKM patients, that is a $72,000 annual reduction ($360,000 gross × 20%). The maximum downward adjustment is capped at 50%, meaning no organization is fully zeroed out. But persistent sub-50% OAR performance triggers termination risk under the Participation Agreement, which is the more severe consequence.
Multi-track enrollment creates the most attractive revenue density. A beneficiary enrolled in both eCKM and MSK with the same participant generates $360 + $180 = $540/year gross, less the 5% multi-track discount on the lower-cost track ($180 × 5% = $9 reduction), yielding $531/year per patient. At 500 such dual-track patients, gross annual revenue reaches $265,500 — from a population that a virtual cardiometabolic + MSK platform can serve with minimal incremental per-patient cost beyond the first track.
PCP co-management payment economics are secondary but additive. At $30/service with a $10 onboarding modifier, a primary care practice referring 100 patients to ACCESS and billing the maximum three co-management codes per patient per year generates approximately $9,000/year in new, zero-cost-sharing revenue — meaningful in aggregate for large practices but not a primary financial driver.
Recent reporting from Medical Economics (October 2026) indicates that health care leaders are broadly planning around ACCESS but expressing significant doubt about its financial viability in practice. This early-implementation skepticism is consistent with the model's unit economics: organizations accustomed to FFS margins or shared savings distributions will find the per-patient OAP rates unfamiliar and, without high patient volume, insufficient to justify operational investment. The financial case for ACCESS is real but requires organizational discipline on patient volume targets and cost structure that many incumbent provider organizations have not yet demonstrated.
Advantaged organizations: Digital-native care delivery companies with existing commercial chronic care programs (virtual MSK, remote cardiometabolic, app-based behavioral health) are the primary intended beneficiaries. They already have the technology infrastructure, outcome tracking capability, FHIR API competency, and low marginal cost structures that make ACCESS financially viable. Companies like virtual PT platforms or remote hypertension management programs can enter with minimal structural modification.
Disadvantaged organizations: Traditional provider groups (hospital-employed physicians, large multispecialty practices) face three compounding challenges: the FFS Exclusion blocks their existing revenue model for aligned patients, their per-patient operational costs are structurally higher than digital-native competitors, and their existing EMR infrastructure is not optimized for FHIR-based OAP data submission at scale. The HIE connectivity requirement (mandatory by July 6, 2027) and the (g)(10) API requirement add compliance burden that traditional organizations will need to build or buy.
Early implementation evidence points to a technology strategy realignment among ACOs. A joint NAACOS and Innovaccer research report released in October 2026 finds that health care leaders — particularly those operating within ACO structures — are actively shifting their technology strategies in response to ACCESS. This is the first meaningful market signal that the model is reshaping vendor procurement and care management platform decisions, not merely generating regulatory commentary. The practical implication: organizations that delay ACCESS planning risk not just competitive displacement in patient enrollment, but falling behind on the underlying technology infrastructure investments that ACCESS participation requires. Recent coverage from MedCity News frames ACCESS as CMMI's attempt to succeed where broader value-based care has repeatedly stalled — an observation that captures both the model's ambition and the structural barriers that have defeated prior efforts. ACO leaders should treat the NAACOS/Innovaccer finding as a leading indicator: if peers are already retooling technology strategy, the competitive window for early infrastructure advantage is narrowing.
ACO interaction is nuanced and potentially negative if not managed. For 2026–2027, ACCESS OAPs do not affect ACO benchmark calculations under MSSP or ACO REACH. Beginning in 2028, they will be included — meaning ACO benchmark expenditures will reflect ACCESS payments, potentially affecting shared savings calculations. ACO leaders must model this now: beneficiaries referred to ACCESS participants generate a new payment stream that enters ACO benchmarking in year three. Additionally, the Substitute Spend Adjustment creates a direct financial penalty for ACO-aligned beneficiaries who receive FFS services duplicative of ACCESS services — creating friction in the traditional ACO care coordination workflow.
MA plan implications are indirect but real. ACCESS is an Original Medicare model; MA plans cannot participate as payors. However, MA organizations that independently adopt outcome-aligned payment arrangements with contracted providers — explicitly contemplated in the RFA — can use the ACCESS G-code billing infrastructure and reference payer implementation resources CMS will publish. ACCESS effectively creates a payment template that MA plans can replicate contractually without CMS involvement. Plans that move early to offer ACCESS-aligned payment terms gain preferred access to digital health networks that will increasingly prioritize Original Medicare participation over MA contracting complexity. The AHIP engagement with the ACCESS model's implications for health plans (September 2026) signals that payer-side analysis of the model's technology ecosystem effects is now underway at the trade association level — a further indicator that MA plan strategy around ACCESS is becoming an active board-level question, not a background regulatory item.
Physicians: Primary care physicians gain a new, zero-administrative-burden referral pathway and a $30–$40 co-management fee stream with no cost-sharing exposure. The care update requirements (mandatory electronic transmission via Direct Secure Messaging or HIE within 10 days of baseline and 30 days of care completion) mean PCPs will receive structured clinical data on referred patients for the first time in a systematic way. The friction is directional access to the full claims picture of patients' ACCESS-enrolled care — something available only through HIE query access, not passive notification.
Health systems: Systems with employed physician networks face the FFS Exclusion as a direct revenue risk if their groups consider becoming ACCESS participants. Systems that function primarily as referring organizations — sending patients to ACCESS participants — face margin dilution on ancillary services (physical therapy, behavioral health, diabetes education) that fall on the Substitute Spend List. Systems that own or invest in digital health subsidiaries are advantaged; those without digital care assets are not.
Hospitals: ACCESS conditions (hypertension, diabetes, CKD stage 3, chronic MSK pain, depression) are leading drivers of avoidable hospitalization. If ACCESS meaningfully improves outcomes at scale, hospital inpatient volumes in these disease categories face secular pressure. This is a long-horizon risk — 3 to 7 years out — but hospital CFOs monitoring Medicare population health trends should flag ACCESS as a structural demand-side variable, not just a payment policy.
Payer/MA plans: The TEMPO pilot disclosure in the beneficiary notice reference document is the single most forward-looking element in the ACCESS documentation — FDA is actively building a real-world evidence pathway for digital health devices through ACCESS enrollment. MA plans that are slow to adopt ACCESS-aligned payment arrangements risk losing preferred access to digital health organizations that will have CMS-validated outcome data by 2028–2030, creating a transparent performance comparison that MA custom contracting cannot match. Employer market dynamics are reinforcing the same directional shift: a 2026 PHTI survey reported by Fierce Healthcare finds that most employers and health plans are now using performance-based digital health contracts — a commercial market trend that ACCESS formalizes and accelerates for Medicare, and that will increasingly make outcome-contingent payment the standard expectation across all payer relationships with digital health vendors.
ACCESS is not a marginal payment tweak. It is an attempt to permanently alter the supply side of Medicare chronic care by making digital-native organizations financially viable for the first time. Early implementation evidence confirms that market participants are taking it seriously enough to retool technology strategy — but widespread skepticism about near-term financial payoff suggests the competitive advantage will accrue disproportionately to organizations that solve the volume and cost-structure problem early, before the field consolidates around proven operational models.